// App-Quantinova.ai

TPS11580 : A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).

Researchers

Presenter

  • Makoto Endo

Principal Investigators

  • Yoshihiro Matsumoto

  • Hiroaki Hiraga

  • Shintaro Iwata

  • Satoshi Tsukushi

  • Munenori Watanuki

  • Toru Akiyama

  • Tsukasa Yonemoto

  • Robert Nakayama

  • Keisuke Ae

  • Hiroyuki Kawashima

  • Hiroyuki Tsuchiya

  • Hirohisa Katagiri

  • Akihito Nagano

  • Satoshi Takenaka

  • Tomoko Kataoka

  • Ryunosuke Machida

  • Haruhiko Fukuda

  • Toshifumi Ozaki

Medical Centers

  • Fukuoka University Hospital, Fukuoka, Japan

  • Niigata University School of Medicine, Niigata, Japan

  • Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

  • National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Tohoku University, Miyagi, Japan

  • Saitama Medical Center, Jichi Medical University, Saitama, Japan

  • Chiba Cancer Center, Chiba, Japan

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • Nigata University Graduate School of Medical and Dental Sciences, Japan

  • Kanazawa University, Kanazawa, Japan

  • Shizuoka Cancer Center Hospital, Shizuoka, Japan

  • Gifu Univ. Graduate School of Medicine, Gifu, Japan

  • Osaka International Cancer Institute, Osaka, Japan

  • National Kyushu Cancer Center, Japan

  • Tokyo, Japan

  • Japan Clinical Oncology Group Data Center, National Cancer Center, Tokyo, Japan

  • Japan Clinical Oncology Group Data Center, National Cancer Center, Tokyo, Japan

  • Okayama University Graduate School, Okayama, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Soft tissue sarcoma

  • Myxoid liposarcoma

  • Ewing's sarcoma

  • Liposarcomas

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Trabectedin

  • Doxorubicin

  • Docetaxel

  • Pazopanib

  • Eribulin

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • II

Study Id's

  • JCOG1802

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved